Medical Staff Pulse Newsletter

Recognition for Arena, Charlton, Jones, Karlan, Spiegel

Elizabeth A. Arena, MD, has been awarded board certification in complex general surgical oncology, Timothy P. Charlton, MD, represented the American Academy of Orthopaedic Surgeons this month in Washington, Heather Jones, MD, has received a grant from the National Institutes of Health for lung research, Beth Y. Karlan, MD, will receive the 2015 Distinguished Service Award from the Society of Gynecologic Oncology, and Brennan Spiegel, MD, MSHS, has been named co-editor-in-chief of The American Journal of Gastroenterology.

» Read more

Meetings and Events

Grand Rounds

Click here to view upcoming grand rounds.

Upcoming CME Conferences

Click below to view a complete list of all scheduled Continuing Medical Education conferences.

CME Newsletter - March 2015 (PDF)


Do you know of a significant event in the life of a medical staff member? Please let us know, and we'll post these milestones in Medical Staff Pulse. Also, feel free to submit comments on milestones, and we'll post the comments in the next issue. Click here to email us your milestones and comments.

» Read more

Share Your News

Won any awards or had an article accepted for publication? Share your news about professional achievements and other items of interest.

Click here to share your news

P & T Approvals, FDA Warning About Sofosbuvir

Pharmacy Focus

Highlights of the February meeting of the Pharmacy and Therapeutics Committee are summarized in the PDF link below. Also, the U.S. Food and Drug Administration has issued a warning about hepatitis C drugs containing sofosbuvir.

P & T Approvals - February 2015 (PDF)

FDA: Sofosbuvir/Amiodarone Combination Can Lead to Bradycardia

The FDA is recommending that drugs containing sofosbuvir, such as Sovaldi and Harvona, not be prescribed concurrently with the antiarrhythmic drug amiodarone. Bradycardia — serious slowing of the heart rate — can occur when the drugs are taken together, according to the FDA. If alternative treatment options are unavailable, the FDA recommends heart monitoring in an inpatient hospital setting for the first 48 hours. Subsequently, monitoring in a doctor’s office or self-monitoring of the heart rate should take place every day through at least the first two weeks of treatment.

For more information, click here.